Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
复制标题
DOI：
10.1136/jitc-2021-003683
复制
发表时间：
2021-11
影响因子：
10.9
通讯作者：
Morris LGT
中科院分区：
文献类型：
--
作者：
Hsiehchen D;Espinoza M;Valero C;Ahn C;Morris LGT
FDA批准用于肿瘤突变负荷（TMB）至少为10 mut/Mb的癌症的免疫检查点抑制剂，旨在通过广泛扩大治疗资格来减少医疗保健差异。在具有可用基因组和种族数据的39，400例患者的队列中，基于当前批准的临界值，黑人和亚洲患者在多种类型的恶性肿瘤中不太可能患有TMB高癌症。降低TMB阈值优先增加了少数患者接受免疫检查点抑制剂治疗的资格，同时保留了免疫检查点抑制剂治疗患者队列中治疗获益的预测值。这项研究强调了TMB高癌症在种族群体之间的不同分布，并为制定更合理的免疫检查点抑制剂资格标准提供了指导。
The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden (TMB) of at least 10 mut/Mb is postulated to reduce healthcare disparities by broadly expanding treatment eligibility. In a cohort of 39,400 patients with available genomic and race data, black and Asian patients were less likely to have TMB-high cancers in multiple types of malignancies based on the currently approved cut-off. Decreasing TMB thresholds preferentially increased the eligibility of minority patients for immune checkpoint inhibitors while retaining predictive value of treatment benefit in a cohort of immune checkpoint inhibitor treated patients. This study highlights differing distributions of TMB-high cancers between racial groups and provides guidance in developing more rational eligibility criteria for immune checkpoint inhibitors.
登录
查看更多内容
影响因子：
50.3
作者：
Carrot-Zhang, Jian;Chambwe, Nyasha;Beroukhim, Rameen
通讯作者：
Beroukhim, Rameen
影响因子：
30.8
作者：
Valero C;Lee M;Hoen D;Wang J;Nadeem Z;Patel N;Postow MA;Shoushtari AN;Plitas G;Balachandran VP;Smith JJ;Crago AM;Long Roche KC;Kelly DW;Samstein RM;Rana S;Ganly I;Wong RJ;Hakimi AA;Berger MF;Zehir A;Solit DB;Ladanyi M;Riaz N;Chan TA;Seshan VE;Morris LGT
通讯作者：
Morris LGT
癌症免疫学。突变景观决定了非小细胞肺癌中对PD-1阻滞的敏感性。
DOI：
10.1126/science.aaa1348
发表时间：
2015-04-03
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Rizvi NA;Hellmann MD;Snyder A;Kvistborg P;Makarov V;Havel JJ;Lee W;Yuan J;Wong P;Ho TS;Miller ML;Rekhtman N;Moreira AL;Ibrahim F;Bruggeman C;Gasmi B;Zappasodi R;Maeda Y;Sander C;Garon EB;Merghoub T;Wolchok JD;Schumacher TN;Chan TA
通讯作者：
Chan TA
DOI：
10.1056/nejmoa1406498
发表时间：
2014-12-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Snyder A;Makarov V;Merghoub T;Yuan J;Zaretsky JM;Desrichard A;Walsh LA;Postow MA;Wong P;Ho TS;Hollmann TJ;Bruggeman C;Kannan K;Li Y;Elipenahli C;Liu C;Harbison CT;Wang L;Ribas A;Wolchok JD;Chan TA
通讯作者：
Chan TA
影响因子：
10.9
作者：
Merino, Diana M.;Mcshane, Lisa M.;Allen, Jeff
通讯作者：
Allen, Jeff